In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $15.52 up 3.33% from its previous closing price of $15.02. In other words, the price has increased by $+0.50 from its previous closing price. On the day, 906355 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.72 and its Current Ratio is at 12.72. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on April 25, 2023, Downgraded its rating to Underperform and sets its target price to $9 from $34 previously.
On February 08, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 25 ’24 when Blackman Samuel C. sold 10,000 shares for $16.01 per share. The transaction valued at 160,055 led to the insider holds 1,184,662 shares of the business.
Blackman Samuel C. sold 30,000 shares of DAWN for $457,314 on Mar 11 ’24. The HEAD OF R&D now owns 1,194,662 shares after completing the transaction at $15.24 per share. On Feb 27 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 20,000 shares for $16.11 each. As a result, the insider received 322,166 and left with 1,224,662 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1.36B and an Enterprise Value of 990.27M.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $17.85, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is 15.04, while the 200-Day Moving Average is calculated to be 13.29.
Shares Statistics:
For the past three months, DAWN has traded an average of 578.44K shares per day and 868.36k over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 58.93M. Insiders hold about 32.57% of the company’s shares, while institutions hold 76.21% stake in the company. Shares short for DAWN as of Feb 29, 2024 were 9.7M with a Short Ratio of 16.78, compared to 9.15M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.10% and a Short% of Float of 17.52%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.71, while EPS last year was -$0.59. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.56 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.27 and -$2.89 for the fiscal current year, implying an average EPS of -$2.62. EPS for the following year is -$2.01, with 9 analysts recommending between -$1.21 and -$2.78.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $74.32M in the next fiscal year. The high estimate is $148.9M and the low estimate is $15.1M. The average revenue growth estimate for next year is up 468.60% from the average revenue estimate for this year.
